骨质疏鬆症药物市场报告：2030 年趋势、预测与竞争分析

骨质疏鬆症治疗药物的趋势与预测

预计到 2030 年，全球骨质疏鬆药物市场将达到 172 亿美元，2024 年至 2030 年年复合成长率为 3.2%。这个市场的主要驱动因素是全球骨质疏鬆症发病率的增加和老年人口的增加。全球骨质疏鬆药物市场前景广阔，骨质疏鬆原发性和续发性市场都有商机。

。

骨质疏鬆症治疗药物市场洞察

Lucintel 预计 RANKL 抑制剂在预测期内仍将是最大的细分市场，因为越来越多地采用 RANKL 抑制剂来治疗骨折高风险患者的骨质疏鬆症。

由于人口迅速高龄化和消费者对骨质疏鬆症认识的不断提高，原发性骨质疏鬆症预计将继续占据市场的很大一部分。

由于主要参与者的存在、骨质疏鬆症患者数量的增加以及该地区品牌药物的容易获得，预计北美在整个预测期内仍将是最大的地区。

本报告回答了 11 个关键问题：

• Q.1. 细分市场中最有前途和高成长的机会是什么？
• Q.2.哪个细分市场将以更快的速度成长？为什么？
• Q.3.您认为哪些地区未来会出现更快的成长？为什么？
• Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
• Q.5. 这个市场的商业风险和竞争威胁是什么？
• Q.6.这个市场有哪些新趋势？为什么？
• Q.7.市场客户需求有何改变？
• Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
• Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
• Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
• Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球骨质疏鬆药物市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球骨质疏鬆治疗药物市场趋势（2018-2023）与预测（2024-2030）
• 按药物类型分類的全球骨质疏鬆药物市场
  • 副甲状腺素治疗
  • 双磷酸盐
  • 降钙素
  • RANKL抑制剂
  • 其他的
• 全球骨质疏鬆症药物市场按应用
  • 原发性骨质疏鬆症
  • 续发性骨质疏鬆症

第4章2018-2030年分地区市场趋势及预测分析

• 全球骨质疏鬆药物市场按地区
• 北美骨质疏鬆药物市场
• 欧洲骨质疏鬆药物市场
• 亚太骨质疏鬆药物市场
• 其他地区骨质疏鬆药物市场

第5章竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第6章成长机会与策略分析

• 成长机会分析
  • 全球骨质疏鬆症药物市场成长机会（依药物类型）
  • 全球骨质疏鬆症药物市场成长机会（按应用）
  • 全球骨质疏鬆药物市场按地区成长机会
• 全球骨质疏鬆药物市场新趋势
• 战略分析
  • 新产品开发
  • 扩大全球骨质疏鬆药物市场的产能
  • 全球骨质疏鬆药物市场的合併、收购与合资
  • 认证和许可

第7章主要企业概况

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Osteoporosis Drug Trends and Forecast

The future of the global osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets. The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

.

A more than 150-page report is developed to help in your business decisions.

Osteoporosis Drug by Segment

The study includes a forecast for the global osteoporosis drug by drug type, application, and region.

Osteoporosis Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Rankl Inhibitors
• Others

Osteoporosis Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Primary Osteoporosis
• Secondary Osteoporosis

Osteoporosis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Osteoporosis Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies osteoporosis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the osteoporosis drug companies profiled in this report include-

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Osteoporosis Drug Market Insights

Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Within this market, primary osteoporosis will remain the larger segment due to surging aging population and growing awareness towards osteoporosis among consumers.

North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Features of the Global Osteoporosis Drug Market

Market Size Estimates: Osteoporosis drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Osteoporosis drug market size by drug type, application, and region in terms of value ($B).

Regional Analysis: Osteoporosis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the osteoporosis drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the osteoporosis drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the osteoporosis drug market size?

Answer: The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030.

Q2. What is the growth forecast for osteoporosis drug market?

Answer: The global osteoporosis drug market is expected to grow with a CAGR of 3.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the osteoporosis drug market?

Answer: The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.

Q4. What are the major segments for osteoporosis drug market?

Answer: The future of the osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets.

Q5. Who are the key osteoporosis drug market companies?

Answer: Some of the key osteoporosis drug companies are as follows:

• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries

Q6. Which osteoporosis drug market segment will be the largest in future?

Answer: Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.

Q7. In osteoporosis drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the osteoporosis drug market by drug type (parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL inhibitors, and others), application (primary osteoporosis and secondary osteoporosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Osteoporosis Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Osteoporosis Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Osteoporosis Drug Market by Drug Type
  • 3.3.1: Parathyroid Hormone Therapy
  • 3.3.2: Bisphosphonates
  • 3.3.3: Calcitonin
  • 3.3.4: RANKL Inhibitors
  • 3.3.5: Others
• 3.4: Global Osteoporosis Drug Market by Application
  • 3.4.1: Primary Osteoporosis
  • 3.4.2: Secondary Osteoporosis

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Osteoporosis Drug Market by Region
• 4.2: North American Osteoporosis Drug Market
  • 4.2.2: North American Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.3: European Osteoporosis Drug Market
  • 4.3.1: European Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.3.2: European Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.4: APAC Osteoporosis Drug Market
  • 4.4.1: APAC Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.4.2: APAC Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
• 4.5: ROW Osteoporosis Drug Market
  • 4.5.1: ROW Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
  • 4.5.2: ROW Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Osteoporosis Drug Market by Drug Type
  • 6.1.2: Growth Opportunities for the Global Osteoporosis Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Osteoporosis Drug Market by Region
• 6.2: Emerging Trends in the Global Osteoporosis Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Osteoporosis Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Osteoporosis Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Eli Lily
• 7.3: F. Hoffmann La Roche
• 7.4: Merck
• 7.5: Amgen
• 7.6: Radius Health
• 7.7: Teva Pharmaceutical Industries